Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK
Open Access
- 29 July 2003
- journal article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 89 (3), 437-454
- https://doi.org/10.1038/sj.bjc.6601106
Abstract
No abstract availableKeywords
This publication has 134 references indexed in Scilit:
- “Be brilliant!”—a tribute to Tom ConnorsEuropean Journal Of Cancer, 2002
- Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in EuropeEuropean Journal Of Cancer, 1995
- Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954European Journal Of Cancer, 1995
- In vivo cultivation of tumor cells in hollow fibersLife Sciences, 1995
- Polymer ConjugatesClinical Pharmacokinetics, 1994
- From triazines and triazenes to temozolomideEuropean Journal Of Cancer, 1993
- EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical modelsEuropean Journal Of Cancer, 1993
- CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cellsBiochemical and Biophysical Research Communications, 1986
- Inhibition of human prostatic tumour acid phosphatase by N,N-p-di-2-chloroethylaminophenol, N,N-p-di-2-chloroethylaminophenyl phosphate and other difunctional nitrogen mustardsChemico-Biological Interactions, 1977
- New platinum complexes with anti-tumour activityChemico-Biological Interactions, 1972